Xenetic Biosciences shares surge 23.23% after-hours after reporting 2025 financial results highlighting DNase technology advancements and preclinical data supporting cancer treatment potential.

Xenetic Biosciences surged 23.23% in after-hours trading following the release of its full-year 2025 financial results and key scientific updates. The company highlighted progress in its DNase-based immuno-oncology platform, including preclinical evidence supporting neutrophil extracellular traps (NETs) as cancer progression drivers and therapeutic potential of DNase interventions. Notably, it advanced investigator-initiated studies in Israel evaluating DNase I in combination with immunotherapies for pancreatic cancer and lymphoma, while moving toward U.S. Investigational New Drug (IND) application. Royalty revenue from its sublicense with Takeda increased 19% to $3.0 million, and the company ended 2025 with $7.9 million in cash, boosted by a $4.0 million public offering. These developments, coupled with strategic efforts to create shareholder value, likely fueled investor optimism about the pipeline’s clinical potential and operational progress.